Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting

(Oxfordshire, UK and Pennsylvania and Maryland, US, 16 May 2019) Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research programme at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 3 June 2019. Tebentafusp (IMCgp100) is a novel bispecific biologic T cell receptor therapy with an anti-CD3 immune-redirecting effector function and specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.